Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260191 · ClinicalTrials.gov registry record · Phase 1
Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04260191 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 15 participants.
The verdict
NCT04260191, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
Interventions
- DRUG AMG 910
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2022-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04260191
The ClinicalTrials.gov registry entry for NCT04260191 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 910 is the first listed.
NCT04260191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04260191 about?
NCT04260191 is a clinical study titled "Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma". To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
What is the current status of trial NCT04260191?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2020-06-29. Estimated completion is 2022-06-02.
What interventions are being tested in trial NCT04260191?
The interventions under investigation include: AMG 910 (DRUG).
Who is sponsoring clinical trial NCT04260191?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.